ZA200106945B - Kit for radiolabeling proteins with Yttrium-90. - Google Patents
Kit for radiolabeling proteins with Yttrium-90. Download PDFInfo
- Publication number
- ZA200106945B ZA200106945B ZA200106945A ZA200106945A ZA200106945B ZA 200106945 B ZA200106945 B ZA 200106945B ZA 200106945 A ZA200106945 A ZA 200106945A ZA 200106945 A ZA200106945 A ZA 200106945A ZA 200106945 B ZA200106945 B ZA 200106945B
- Authority
- ZA
- South Africa
- Prior art keywords
- kit
- dtpa
- chelator
- buffer
- antibody
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 65
- 108090000623 proteins and genes Proteins 0.000 title claims description 65
- 238000000163 radioactive labelling Methods 0.000 title claims description 52
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 title description 9
- 238000000034 method Methods 0.000 claims description 67
- 235000018102 proteins Nutrition 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 239000002738 chelating agent Substances 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 30
- 239000012537 formulation buffer Substances 0.000 claims description 30
- 239000001632 sodium acetate Substances 0.000 claims description 30
- 235000017281 sodium acetate Nutrition 0.000 claims description 30
- 230000001225 therapeutic effect Effects 0.000 claims description 24
- 238000011534 incubation Methods 0.000 claims description 20
- 238000000746 purification Methods 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 15
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 229940124553 radioprotectant Drugs 0.000 claims description 12
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 claims description 10
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 229940072107 ascorbate Drugs 0.000 claims description 7
- 230000001588 bifunctional effect Effects 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- OBWILOKKNDYPLX-HBMCJLEFSA-N (1S,2S,5S)-2-(4-glutaridylbenzyl)-5-phenylcyclohexan-1-ol Chemical compound C1([C@H]2CC[C@@H](C[C@@H]2O)C=2C=CC=CC=2)=CC=C(C(=O)NCCCC(O)=O)C=C1 OBWILOKKNDYPLX-HBMCJLEFSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960005219 gentisic acid Drugs 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 3
- 229960002433 cysteine Drugs 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 37
- 238000002360 preparation method Methods 0.000 description 33
- 239000003153 chemical reaction reagent Substances 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 22
- 238000003608 radiolysis reaction Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000013024 dilution buffer Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 229910052727 yttrium Inorganic materials 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 8
- -1 polypropylene Polymers 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 239000008229 sterile water for irrigation Substances 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 238000011363 radioimmunotherapy Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960005570 pemtumomab Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
- OBOSXEWFRARQPU-UHFFFAOYSA-N 2-n,2-n-dimethylpyridine-2,5-diamine Chemical compound CN(C)C1=CC=C(N)C=N1 OBOSXEWFRARQPU-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZVGCGHVMJAECEG-UHFFFAOYSA-N Chinol Natural products COC1=C(O)C(C)=C(C)C(O)=C1OC ZVGCGHVMJAECEG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010015804 indium-111-DOTA-peptide chimeric L6 Proteins 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- VRYGRLBNIVQXMY-UHFFFAOYSA-M sodium;acetic acid;chloride Chemical compound [Na+].[Cl-].CC(O)=O VRYGRLBNIVQXMY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 108010026050 yttrium-90-DOTA-peptide-chimeric L6 Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25933899A | 1999-03-01 | 1999-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106945B true ZA200106945B (en) | 2002-11-22 |
Family
ID=22984528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106945A ZA200106945B (en) | 1999-03-01 | 2001-08-22 | Kit for radiolabeling proteins with Yttrium-90. |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US6994840B1 (ru) |
| EP (2) | EP1156835B1 (ru) |
| JP (1) | JP4558947B2 (ru) |
| KR (1) | KR100734023B1 (ru) |
| CN (1) | CN1251767C (ru) |
| AT (1) | ATE428446T1 (ru) |
| AU (1) | AU780311B2 (ru) |
| BG (1) | BG65568B1 (ru) |
| BR (1) | BR0008635A (ru) |
| CA (1) | CA2362908C (ru) |
| CY (1) | CY1109211T1 (ru) |
| CZ (1) | CZ20013127A3 (ru) |
| DE (2) | DE1156835T1 (ru) |
| DK (1) | DK1156835T3 (ru) |
| EE (1) | EE05582B1 (ru) |
| ES (1) | ES2165830T3 (ru) |
| GR (1) | GR20010300078T1 (ru) |
| HK (1) | HK1045656B (ru) |
| HR (1) | HRP20010713A2 (ru) |
| HU (1) | HU227986B1 (ru) |
| IL (2) | IL145112A0 (ru) |
| ME (1) | ME00783B (ru) |
| MX (1) | MXPA01008745A (ru) |
| MY (1) | MY133346A (ru) |
| NO (1) | NO330728B1 (ru) |
| NZ (1) | NZ513667A (ru) |
| PL (1) | PL204239B1 (ru) |
| PT (1) | PT1156835E (ru) |
| RS (1) | RS50342B (ru) |
| RU (1) | RU2221807C2 (ru) |
| SI (1) | SI1156835T1 (ru) |
| SK (1) | SK287650B6 (ru) |
| TW (1) | TWI283178B (ru) |
| UA (1) | UA75036C2 (ru) |
| WO (1) | WO2000052031A2 (ru) |
| ZA (1) | ZA200106945B (ru) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102208A1 (en) * | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| EP1322383B9 (en) | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| US6696060B2 (en) * | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| US7252799B2 (en) | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| US6783968B2 (en) | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US6974563B2 (en) | 2002-06-18 | 2005-12-13 | Lynntech, Inc. | Ion exchange materials for the separation of 90Y from 90SR |
| CA2514062A1 (en) * | 2003-01-27 | 2004-08-12 | Biogen Idec Ma Inc. | Compositions and methods for treating cancer using igsf9 and liv-1 |
| ZA200507983B (en) * | 2003-04-15 | 2007-03-28 | Algetaas | Thorium-227 for use in radiotherapy of soft tissue disease |
| WO2005044855A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| EP2236172A1 (en) | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| EP2248830A1 (en) | 2003-11-04 | 2010-11-10 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| EP1680141B8 (en) | 2003-11-04 | 2011-01-12 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| DK1682177T3 (da) | 2003-11-04 | 2010-11-01 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi |
| EP1889065B1 (en) | 2005-05-18 | 2013-07-10 | Novartis AG | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
| CA2649907A1 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| MX2011000542A (es) | 2008-07-16 | 2011-08-03 | Humabs Llc | Citomegalovirus humano que neutraliza anticuerpos y su uso. |
| MX343490B (es) | 2008-07-16 | 2016-11-08 | Inst For Res In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos. |
| KR101732056B1 (ko) | 2008-07-25 | 2017-05-02 | 인스티튜트 포 리서치 인 바이오메드슨 | 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| NZ592054A (en) | 2008-10-13 | 2013-06-28 | Inst Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| US20110212106A1 (en) | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| WO2011147762A2 (en) * | 2010-05-25 | 2011-12-01 | Bayer Pharma Aktiengesellschaft | Stabilized radiopharmaceutical composition |
| EP2654803B1 (en) * | 2010-12-22 | 2021-08-18 | General Electric Company | Radiolabeled her2-binding peptide conjugates |
| US9587010B2 (en) | 2011-07-18 | 2017-03-07 | The Institute For Research In Biomedicine | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP2828293B1 (en) | 2012-03-20 | 2017-10-25 | Humabs Biomed S.A. | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
| RU2537175C2 (ru) * | 2013-03-26 | 2014-12-27 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | Способ получения радиоиммунного препарата для диагностики и терапии онкологических заболеваний |
| KR20160035077A (ko) | 2013-08-13 | 2016-03-30 | 사노피 | 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도 |
| RU2683498C2 (ru) | 2013-10-02 | 2019-03-28 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа а и пути их применения |
| RU2739952C2 (ru) | 2014-07-15 | 2020-12-30 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа b и пути их применения |
| US20170296650A1 (en) | 2014-10-08 | 2017-10-19 | Novartis Ag | Combination of human cytomegalovirus neutralizing antibodies |
| WO2016075546A2 (en) | 2014-11-14 | 2016-05-19 | Antonio Lanzavecchia | Antibodies that neutralize ebola virus and uses thereof |
| ES2838679T3 (es) | 2014-11-18 | 2021-07-02 | Humabs Biomed S A | Anticuerpos que neutralizan de forma potente el virus de la rabia y otros lisavirus y su utilización |
| IL237525A (en) * | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| GB201504064D0 (en) | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
| SI3303384T1 (sl) | 2015-06-01 | 2021-11-30 | Medimmune Llc | Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba |
| WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EP3402513A4 (en) | 2016-01-13 | 2019-10-23 | Medlmmune, LLC | METHOD OF TREATING A FLU |
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| EP3612562A2 (en) | 2017-04-19 | 2020-02-26 | Institute for Research in Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| WO2018209346A1 (en) * | 2017-05-12 | 2018-11-15 | Memorial Sloan-Kettering Cancer Center | Use of anti-b7h3 antibodies for treating cancer in the central nervous system |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
| HRP20231440T1 (hr) | 2018-12-19 | 2024-03-01 | Humabs Biomed Sa | Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba |
| KR20220063188A (ko) | 2019-08-29 | 2022-05-17 | 비르 바이오테크놀로지, 인코포레이티드 | B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법 |
| CN111116701A (zh) * | 2019-11-14 | 2020-05-08 | 浙江普罗亭健康科技有限公司 | 一种用于蛋白金属标记的中间体及其制备方法、用途 |
| JP2023531520A (ja) | 2020-06-24 | 2023-07-24 | ヴィア・バイオテクノロジー・インコーポレイテッド | 操作されたｂ型肝炎ウイルス中和抗体およびその使用 |
| TW202245838A (zh) | 2021-01-26 | 2022-12-01 | 美商維爾生物科技股份有限公司 | 用於治療b型肝炎病毒感染的組成物及方法 |
| WO2024068944A1 (en) | 2022-09-30 | 2024-04-04 | Sanofi | Anti-cd28 antibodies |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994966A (en) | 1972-09-28 | 1976-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Chelating agents |
| US4043998A (en) | 1974-10-09 | 1977-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid |
| US4315851A (en) | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4460559A (en) | 1980-03-03 | 1984-07-17 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4460561A (en) | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4622420A (en) | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
| US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4707352A (en) | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group |
| US4636380A (en) | 1984-04-23 | 1987-01-13 | Wong Dennis W | Novel physiologic chemical method of labeling protein substances with the radionuclides of indium |
| US4634586A (en) | 1984-05-21 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reagent and method for radioimaging leukocytes |
| US4722892A (en) | 1984-08-31 | 1988-02-02 | Meares Claude F | Monoclonal antibodies against metal chelates |
| US4824986A (en) | 1985-04-26 | 1989-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metal chelate protein conjugate |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4926869A (en) | 1986-01-16 | 1990-05-22 | The General Hospital Corporation | Method for the diagnosis and treatment of inflammation |
| DK172629B1 (da) | 1986-02-14 | 1999-03-22 | Nihon Mediphysics Co Ltd | Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk |
| EP0529645B1 (en) * | 1986-09-05 | 1996-10-23 | GANSOW, Otto A. | Process for the preparation of backbone polysubstituted chelates |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5034223A (en) | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US4921690A (en) | 1986-12-29 | 1990-05-01 | City Of Hope | Method of enhancing the biodistribution of antibody for localization in lesions |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU619218B2 (en) | 1987-11-06 | 1992-01-23 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US5130118A (en) | 1987-11-06 | 1992-07-14 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US5217704A (en) | 1987-11-06 | 1993-06-08 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| WO1992011864A1 (en) | 1991-01-11 | 1992-07-23 | Cryopharm Corporation | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material |
| JPH0720989B2 (ja) | 1988-05-25 | 1995-03-08 | アメリカ合衆国 | 大環状キレート化合物の抱合体と診断的テスト方法 |
| US4923985A (en) | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| US5059518A (en) | 1988-10-20 | 1991-10-22 | Coulter Corporation | Stabilized lyophilized mammalian cells and method of making same |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5376356A (en) | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| US5162115A (en) | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| US5219556A (en) | 1990-07-09 | 1993-06-15 | Mallinckrodt Medical, Inc. | Stabilized therapeutic radiopharmaceutical complexes |
| US5009069A (en) | 1990-08-24 | 1991-04-23 | Molini Alberto E | Method of recovering energy from ocean water |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| CA2095141A1 (en) | 1990-11-05 | 1992-05-06 | Ingegerd Hellstrom | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents |
| US5208008A (en) | 1990-11-14 | 1993-05-04 | University Of Pittsburgh | Regioselective chemical modification of monoclonal antibodies |
| US5403573A (en) | 1992-04-23 | 1995-04-04 | The Curators Of The University Of Missouri | Radiolabeled protein composition and method for radiation synovectomy |
| US5541287A (en) | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
| US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5650134A (en) * | 1993-01-12 | 1997-07-22 | Novartis Ag (Formerly Sandoz Ltd.) | Peptides |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5766751A (en) * | 1994-01-24 | 1998-06-16 | Sumitomo Chemical Company, Ltd. | Laminate, laminate film and shaped article comprising inorganic laminar compound |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5686578A (en) | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US5942210A (en) * | 1994-11-15 | 1999-08-24 | Cytogen Corporation | Methods for lyoprotecting a macromolecule using tricine |
| US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US6300143B1 (en) | 1999-03-01 | 2001-10-09 | Idec Pharmaceuticals Corporation | Electrochemiluminescent assays for eukaryotic cells |
-
2000
- 2000-02-28 MY MYPI20000752A patent/MY133346A/en unknown
- 2000-02-29 EE EEP200100461A patent/EE05582B1/xx unknown
- 2000-02-29 NZ NZ513667A patent/NZ513667A/en not_active IP Right Cessation
- 2000-02-29 ES ES00919345T patent/ES2165830T3/es not_active Expired - Lifetime
- 2000-02-29 CZ CZ20013127A patent/CZ20013127A3/cs unknown
- 2000-02-29 RS YUP-617/01A patent/RS50342B/sr unknown
- 2000-02-29 AT AT00919345T patent/ATE428446T1/de active
- 2000-02-29 PT PT00919345T patent/PT1156835E/pt unknown
- 2000-02-29 AU AU40046/00A patent/AU780311B2/en not_active Expired
- 2000-02-29 JP JP2000602256A patent/JP4558947B2/ja not_active Expired - Lifetime
- 2000-02-29 EP EP00919345A patent/EP1156835B1/en not_active Expired - Lifetime
- 2000-02-29 SK SK1217-2001A patent/SK287650B6/sk not_active IP Right Cessation
- 2000-02-29 DE DE1156835T patent/DE1156835T1/de active Pending
- 2000-02-29 WO PCT/US2000/005078 patent/WO2000052031A2/en active IP Right Grant
- 2000-02-29 PL PL350551A patent/PL204239B1/pl unknown
- 2000-02-29 UA UA2001086058A patent/UA75036C2/ru unknown
- 2000-02-29 MX MXPA01008745A patent/MXPA01008745A/es active IP Right Grant
- 2000-02-29 TW TW089103477A patent/TWI283178B/zh not_active IP Right Cessation
- 2000-02-29 SI SI200031032T patent/SI1156835T1/sl unknown
- 2000-02-29 RU RU2001126396/04A patent/RU2221807C2/ru active
- 2000-02-29 DK DK00919345T patent/DK1156835T3/da active
- 2000-02-29 KR KR1020017011085A patent/KR100734023B1/ko active IP Right Grant
- 2000-02-29 IL IL14511200A patent/IL145112A0/xx active IP Right Grant
- 2000-02-29 HU HU0105489A patent/HU227986B1/hu unknown
- 2000-02-29 DE DE60042014T patent/DE60042014D1/de not_active Expired - Lifetime
- 2000-02-29 BR BR0008635-5A patent/BR0008635A/pt not_active Application Discontinuation
- 2000-02-29 ME MEP-2009-22A patent/ME00783B/me unknown
- 2000-02-29 CN CNB00805729XA patent/CN1251767C/zh not_active Expired - Lifetime
- 2000-02-29 EP EP08105278A patent/EP2011520A1/en not_active Withdrawn
- 2000-02-29 CA CA2362908A patent/CA2362908C/en not_active Expired - Lifetime
- 2000-07-28 US US09/628,186 patent/US6994840B1/en not_active Expired - Lifetime
-
2001
- 2001-08-22 ZA ZA200106945A patent/ZA200106945B/en unknown
- 2001-08-24 IL IL145112A patent/IL145112A/en not_active IP Right Cessation
- 2001-08-29 BG BG105853A patent/BG65568B1/bg unknown
- 2001-08-31 NO NO20014239A patent/NO330728B1/no not_active IP Right Cessation
- 2001-10-01 HR HR20010713A patent/HRP20010713A2/hr active Application Revival
-
2002
- 2002-01-31 GR GR20010300078T patent/GR20010300078T1/el unknown
- 2002-10-03 HK HK02107257.1A patent/HK1045656B/zh not_active IP Right Cessation
-
2005
- 2005-07-15 US US11/181,811 patent/US7229620B2/en not_active Expired - Lifetime
-
2007
- 2007-06-08 US US11/760,503 patent/US7618613B2/en not_active Expired - Fee Related
-
2009
- 2009-07-07 CY CY20091100722T patent/CY1109211T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU780311B2 (en) | Kit for radiolabeling proteins with yttrium-90 | |
| DK2112512T3 (en) | Kit for radiolabeling and binding assay |